Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 52, 6341-6347, November 15, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perez-Soler, R.
Right arrow Articles by Khokhar, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perez-Soler, R.
Right arrow Articles by Khokhar, A. R.

Lipophilic Cisplatin Analogues Entrapped in Liposomes: Role of Intraliposomal Drug Activation in Biological Activity1

Roman Perez-Soler2 and Abdul R. Khokhar

Department of Medical Oncology (Section of Head, Neck, and Thoracic Medical Oncology [R. P-S.] and Section of Pharmacology [A. R. K.]), The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (NDDP), a lipophilic cisplatin analogue containing two branched leaving groups of 10 carbon atoms, is undergoing clinical evaluation in a liposomal formulation. In previous studies, NDDP entrapped in multilamellar vesicles composed of dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) at a 7:3 molar ratio was non-nephrotoxic in humans, not cross-resistant with cisplatin in different in vitro and in vivo systems, and more active than cisplatin against murine models of experimental liver metastases whereas free NDDP was devoid of in vivo antitumor activity at the optimal dose of L-NDDP and barely active at higher doses. To elucidate the mechanisms by which the liposomal carrier enhances the biological properties to this class of antitumor agents, we studied the effect of the liposome composition, size of the branched leaving groups of the platinum compound, and pH and composition of the aqueous phase on the entrapment efficiency, drug leakage, drug stability, and in vivo toxicity and antitumor activity of different liposomal formulations of these agents. In experiments using normal saline as aqueous phase, the presence of DMPG in the lipid bilayer resulted in a decreased stability and an increased biological activity of NDDP, whereas NDDP entrapped in liposomes composed of DMPC alone (not containing DMPG) was stable but devoid of antitumor activity. In studies with structurally related analogues with branched leaving groups of 5, 6, 7, and 9 carbon atoms, similar trends were observed. In addition, the number of carbon atoms in the leaving groups was directly and inversely related to the entrapment efficiency and stability of the analogues, respectively, independently of lipid composition; increasing the size of the branched leaving groups resulted in an increased in situ degradation of the platinum compound and enhanced biological activity and potency. These results suggest that this class of platinum compounds exerts its biological activity through the formation of active intermediates in situ within the lipid bilayers and that the activation reaction is highly dependent on the presence of DMPG and the size of the lipophilic leaving group.

1 This study was supported in part by Grants CA 45423 and CA 41581 from the National Cancer Institute, Department of Health and Human Services, and was presented in part at the 82nd Annual Meeting of the American Association for Cancer Research, Houston, TX, 1991.

2 To whom requests for reprints should be addressed, at Section of Head, Neck, and Thoracic Medical Oncology, Department of Medical Oncology, Box 80, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030.

Received 6/16/92. Accepted 9/11/92.




This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
P. M. Furneri, M. Fresta, G. Puglisi, and G. Tempera
Ofloxacin-Loaded Liposomes: In Vitro Activity and Drug Accumulation in Bacteria
Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2458 - 2464.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1992 by the American Association for Cancer Research.